Abstract
relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (abmt) for malignant lymphoma (ml). allogeneic transplantation (allosct) is a therapeutic option. however, it is associated with a high incidence of transplant-related organ toxicity and mortality. we recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to allosct. we now present our experience with 23 heavily treated high risk ml patients who underwent matched allosct following the same low intensity conditioning. the patients (20 male, three female) were aged 13–63 years. nineteen had nhl and four hd (resistant disease 12, partial remission 11). five were post abmt. twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. engraftment was fast. there was no rejection or non-engraftment. organ toxicity was moderate with no liver or renal toxicity >grade ii. four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died – four of grade III–IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15–37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000) 25, 1021–1028.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1555
Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease. Results of a BNLL randomized trial Lancet 1993 341: 1051–1054
Stahel RA, Lorenz MJ, Pichert G et al. High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas Cancer Treat Rev 1995 21: 3–32
Stahel RA, Jost LM, Honegger H et al. Randomized trial showing equivalent efficacy of Filgrastim 5μg/kg/d and 10μg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas J Clin Oncol 1997 15: 1730–1735
Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry Data J Clin Oncol 1992 10: 1690–1695
Shipp MA . Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk’ disease? Blood 1994 83: 1165–1173
Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 1994 83: 1193–1199
Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood 1993 81: 1137–1145
Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients post-autologous marrow or stem cell transplantation Blood 1997 89: 3951–3959
Slavin S, Nagler A . New developments in bone marrow transplantation Curr Opin Oncol 1991 3: 254–271
Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs. leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia Cancer Immunol Immunother 1990 31: 236–242
Weiss L, Lubin I, Factorowich I et al. Effective graft versus leukemia effects independent of graft versus host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma (BCL1): role of cell therapy and recombinant IL-2 J Immunol 1994 153: 2563–2567
Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI) Cancer Immunol Immunother 1981 11: 155–158
Or R, Nagler A, Ackerstein A et al. Allogeneic cell-mediated immunotherapy at the minimal residual disease stage following autologous stem cell transplantation for malignant lymphoma Immunother 1998 21: 447–453
Papadopoulos EB, Landanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 330: 1185–1191
Toren A, Or R, Ackerstein A, Nagler A . Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT) Bone Marrow Transplant 1997 20: 67–69
Slavin S, Nagler A . Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma Ann Oncol 1998 9: S31–39
Phillips GL, Herzig RH, Lazarus HM et al. High dose chemotherapy, fractionated total body irradiation and allogeneic marrow transplantation for malignant lymphoma J Clin Oncol 1986 4: 480–498
Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653
Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 1994 84: 1050–1055
Verdonck LF, Dekker AW, Lokhorts HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201–4205
Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy J Clin Oncol 1995 13: 596–602
Van Besien W, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology Am J Med 1996 100: 299–307
Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease J Clin Oncol 1996 14: 572–578
Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation J Clin Oncol 1996 14: 1291–1296
De Lima M, Van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 1997 19: 121–127
Dann EJ, Daugherty CK, Larson RA . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma Bone Marrow Transplant 1997 20: 369–374
Yang SW, Huang P, Plunkett W . Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate J Biol Chem 1992 267: 2345–2349
Huang P, Plunkett W . Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism Mol Pharmacol 1991 39: 449–455
Robertson LE, Chubb S, Meyn RE . Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinofuranosyl-2-fluoroadenine Blood 1993 81: 143–150
Keating MJ . Fludarabine phosphate: current and future therapeutic applications Semin Oncol 1993 20: 1–31
Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 1991 9: 44–49
Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 1989 74: 19–25
Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma J Clin Oncol 1992 10: 790–794
Hochster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study J Clin Oncol 1992 10: 28–32
Hiddemann W, Unterhalt M, Port C et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphoma: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group Semin Oncol 1993 20: 28–31
Pigaditou A, Rohatiner AZS, Whelan JS et al. Fludarabine in low-grade lymphoma Semin Oncol 1993 20: 24–27
Keating MJ . Immunosuppression with purine analogues – the flip side of the gold coin Ann Oncol 1993 4: 347–348
Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype New Engl J Med 1998 339: 1186–1193
Slavin S, Nagler A, Naparstek E . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Or R, Weiss L, Teiman S, Polliack A . Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation Blood 1997 1: 471–472 (letter)
Gribben JG, Freedman AS, Woo SD et al. All advanced non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275–3280
Pugatsch T, Oppenheim A, Slavin S . Improved single step PCR assay for sex identification post allogeneic sex-mismatched BMT Bone Marrow Transplant 1996 17: 273–275
Nakamura Y, Leppert M, O'Connell P . Variable number of tandem repeat (VNTR) markers for human gene mapping Science 1987 235: 1616–1622
Przepiorka DM, Weisdorf D, Martin P . Consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828
Sullivan KM, Agura E, Anasetti C . Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Oncol 1991 28: 250–259
Bearman SI, Appelbaum FR, Buckner CD . Regimen related toxicity in patients undergoing bone marrow transplantation Clin Oncol 1988 6: 1562–1568
Kaplan E, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 54: 457–481
Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 1996 87: 2195–2204
Nilsson SK, Dooner MS, Tiarks CY et al. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model Blood 1997 89: 4013–4020
Rao SS, Peters SO, Crittenden RB et al. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment Exp Hematol 1997 25: 114–121
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs.-leukemia without myeloablative therapy Blood 1997 89: 4531–4536
McSweeney PA, Wagner JL, Maloney DG et al. Outpatient PBSC allografts using immunosuppression after low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant Blood 1998 92: (Suppl.1) 519a (Abstr.2133)
Woolfrey AE, Nash RA, Frangoul HA et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T cell immunodeficiency Blood 1998 92: (Suppl.1) 520a (Abstr.2135)
Juckett M, Rowlings P, Hessner M et al. T cell-depletedallogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up Bone Marrow Transplant 1998 21: 893–899
Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation Lancet 1999 353: 1755–1759
Falkenburg JHF, Jluin-Nelemans HC . Mismatched transplants for refractory lymphoma? Lancet 1999 353: 1725–1726
Aizawa S, Sado T . Graft-versus-leukemia effect in MHC-compatible and incompatible allogeneic bone marrow transplantations of radiation-induced leukemia-bearing mice Transplantation 1991 51: 885–889
Sykes M, Sachs DH . Genetic analysis of anti-leukemic effect of mixed allogeneic bone marrow transplantation Transplant Proc 1989 21: 3022–3024
Mandigers CM, Raemaekers JM, Schattenberg AV et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma Br J Haematol 1998 100: 198–206.
Acknowledgements
We thank the Baxter Healthcare Corporation, The Gabriella Rich Foundation, Schering AG, and Fresenius AG, for their support of our ongoing basic and clinical research. We also wish to thank Mr and Mrs Melvin Cohen for their generosity in supporting our clinical research.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagler, A., Slavin, S., Varadi, G. et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25, 1021–1028 (2000). https://doi.org/10.1038/sj.bmt.1702392
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702392